Novo Nordisk Issues Supply Notice

Novo Nordisk provided the following update about the NovoSeven® RT (coagulation Factor VIIa, recombinant) 8 mg vial.

Due to supply constraints, Novo Nordisk will be unable to provide the 8 mg vial of NovoSeven® RT from January until mid-2024. Importantly, the overall supply of NovoSeven® RT is expected to remain intact as other vial sizes are available as a solution for those who would otherwise use the 8 mg vial. Patients can use the 1 mg, 2 mg, and 5 mg vials in combination to make the dose they need in absence of the 8 mg vial. Patients who have questions about how to make up their dose should consult their healthcare provider.

This is not a quality issue. Novo Nordisk has decided to temporarily limit supply of the 8 mg vial because it requires the highest amount of Active Pharmaceutical Ingredient (API), which is currently constrained, compared to the other vial sizes. By re-directing the API towards the 1 mg, 2 mg, and 5 mg vial sizes, we can produce more and help ensure the overall supply of NovoSeven® RT remains intact for patients. Again, we don’t expect constraints on supply of the 1 mg, 2 mg, and 5 mg vials that would impact availability for patients.

We recognize the inconvenience this may cause, and we are working hard to restore availability of the 8 mg vial as soon as possible. We are in dialogue with HCPs, advocacy groups, specialty pharmacies, and specialty distributors to minimize the impact this will have on patients.

Read the update in its entirety here.